Evidence map›Paper›PMID 32909014›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: A guide and case study in setting up an emergency-use, laboratory-developed molecular assay.

Melis N Anahtar, Bennett Shaw, Damien Slater, Elizabeth Byrne, Yolanda Botti-Lodovico, Gordon Adams, Stephen Schaffner, Jacqueline Eversley, Graham McGrath, Tasos Gogakos and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Melis N AnahtarDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Bennett ShawBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Damien SlaterDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Elizabeth ByrneBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Yolanda Botti-LodovicoBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Gordon AdamsBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Stephen SchaffnerBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Jacqueline EversleyDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Graham McGrathDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Tasos GogakosDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Jochen LennerzDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Hetal Desai MarbleDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Lauren L RitterhouseDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Julie BattenDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
N Zeke GeorgantasDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Rebecca PellerinDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Sylvia SignorelliDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Julia ThieraufDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Molly KemballBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Christian HappiDepartment of Biological Sciences, Redeemer's University, Ede, Osun State, Nigeria.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Ministry of Health and Sanitation, 1 Combema Road, Kenema, Sierra Leone.
Daouda NdiayeAfrican Center of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria.
Katherine J SiddleBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Samar B MehtaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Jason HarrisDepartment of Pediatrics, Massachusetts General Hospital for Children, Boston, MA, USA.
Edward T RyanDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Virginia PierceDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Regina LaRocqueDepartment of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Jacob E LemieuxBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Pardis SabetiBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Eric RosenbergDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
John BrandaDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Sarah E TurbettDepartment of Pathology and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
West African Emerging Infectious Disease Research Center (WA-EIDRC)U01AI151812 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD, GARRY, ROBERT F · 2020 to 2024
$13.2M
Utilize Microbial Metagenomics for Viral Pathogen CharacterizationU54HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2017 to 2022
$5.5M
NCEZID CDC HHS U01 CK000490NHGRI NIH HHS U54 HG007480NIAID NIH HHS U01 AI151812NIAID NIH HHS U19 AI110818
6 · The paper itself

Abstract

Developing and deploying new diagnostic tests is difficult, but the need to do so in response to a rapidly emerging pandemic such as COVID-19 is crucially important for an effective response. In the early stages of a pandemic, laboratories play a key role in helping health care providers and public health authorities detect active infection, a task most commonly achieved using nucleic acid-based assays. While the landscape of diagnostics is rapidly evolving, polymerase chain reaction (PCR) remains the gold-standard of nucleic acid-based diagnostic assays, in part due to its reliability, flexibility, and wide deployment. To address a critical local shortage of testing capacity persisting during the COVID-19 outbreak, our hospital set up a molecular based laboratory developed test (LDT) to accurately and safely diagnose SARS-CoV-2. We describe here the process of developing an emergency-use LDT, in the hope that our experience will be useful to other laboratories in future outbreaks and will help to lower barriers to fast and accurate diagnostic testing in crisis conditions.

Identifiers

PMID32909014
PMCPMC7480066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.